.png&w=384&q=75)
Cyclizine Hydrochloride is indicated in adults and in children aged 6 years and over for the prevention and treatment of nausea and vomiting including:-
Cyclizine is a histamine H1 receptor antagonist of the piperazine class which is characterised by a low incidence of drowsiness. It possesses anticholinergic and antiemetic properties. The exact mechanism by which cyclizine can prevent or suppress both nausea and vomiting from various causes is unknown. Cyclizine increases lower oesophageal sphincter tone and reduces the sensitivity of the labyrinthine apparatus. It may inhibit the part of the midbrain known collectively as the emetic centre.
Adults: 50 mg orally, which may be repeated up to three times a day.
Children over 12 years of age: 50 mg orally, which may be repeated up to three times a day.
Children 6 to 12 years of age: 25 mg orally, which may be repeated up to three times a day.
Children less than 6 years of age: Cyclizine Hydrochloride tablets are not recommended for children less than 6 years of age.
Cyclizine Hydrochloride may counteract the haemodynamic benefits of opioid analgesics.
Because of its anticholinergic activity cyclizine may enhance the side-effects of other anticholinergic drugs, and have an additive antimuscarinic action with other antimuscarinic drugs, such as atropine and some antidepressants (both tricyclics and MAOIs). Cyclizine Hydrochloride may mask the warning signs of damage caused by ototoxic drugs such as aminoglycoside antibacterials.
Cyclizine is contraindicated in the presence of acute alcohol intoxication. The anti-emetic properties of cyclizine may increase the toxicity of alcohol.
Common side effects may include:
In the absence of any definitive human data, the use of Cyclizine Hydrochloride in pregnancy is not advised.
Cyclizine is excreted in human milk; however, the amount has not been quantified
Symptoms of acute toxicity from cyclizine arise from peripheral anticholinergic effects and effects on the central nervous system.
Peripheral anticholinergic symptoms include dry mouth, nose and throat, blurred vision, tachycardia and urinary retention. Central nervous system effects include drowsiness, dizziness, incoordination, ataxia, weakness, hyperexcitability, disorientation, impaired judgement, hallucinations, hyperkinesia, extrapyramidal motor disturbances, convulsions, hyperpyrexia and respiratory depression.
An oral dose of 5 mg/kg is likely to be associated with at least one of the clinical symptoms stated above. Younger children are more susceptible to convulsions. The incidence of convulsions, in children less than 5 years, is about 60% when the oral dose ingested exceeds 40 mg/kg.
Store below 25°C.
Cyclizine Hydrochloride 50 mg